dc.contributor.author | Ünal, Can Murat | |
dc.contributor.author | Steinert, Michael | |
dc.date.accessioned | 2021-01-08T21:51:28Z | |
dc.date.available | 2021-01-08T21:51:28Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 0304-4165 | |
dc.identifier.issn | 1872-8006 | |
dc.identifier.uri | http://doi.org/10.1016/j.bbagen.2014.12.018 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12846/285 | |
dc.description | Unal, Can/0000-0003-4710-9567 | en_US |
dc.description | WOS:000361263700015 | en_US |
dc.description | PubMed: 25529296 | en_US |
dc.description.abstract | Background: FK506-binding proteins (FKBPs) contain a domain with peptidyl-prolyl-cis/trans-isomerase (PPlase) activity and bind the immunosuppressive drugs FK506 and rapamycin. FKBPs belong to the immunophilin family and are found in eukaryotes and bacteria. Scope of review: In this review we describe two major groups of bacterial virulence-associated FKBPs, the trigger factor and Mip-like PPIases. Moreover, we discuss the contribution of host FKBPs in bacterial infection processes. Major conclusions: Since PPIases are regarded as alternative antiinfective drug targets we highlight current research strategies utilizing pipecolinic acid and cycloheximide derivatives as well as substrate based inhibitors. General significance: The current research strategies suggest a beneficial synergism of drug development and basic research. This article is part of a Special Issue entitled Proline-directed Foldases: Cell Signaling Catalysts and Drug Targets. (C) 2014 Elsevier B.V. All rights reserved. | en_US |
dc.description.sponsorship | TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2219 (2012/2. term)]; State of Lower Saxony, Niedersachsisches Vorab [VWZN2889]; DFGGerman Research Foundation (DFG) [STE838/8-1] | en_US |
dc.description.sponsorship | Can M. Unal is supported by a 2219 (2012/2. term) grant from TUBITAK, and the State of Lower Saxony, Niedersachsisches Vorab (VWZN2889) within the joint research project "CDiff: Epidemiology and systems biology of the bacterial pathogen Clostridium difficile". Michael Steinert is funded by the DFG grant STE838/8-1. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Science Bv | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Fk506-Binding Protein | en_US |
dc.subject | Macrophage Infectivity Potentiator (Mip) | en_US |
dc.subject | Bacteria | en_US |
dc.subject | Pathogen | en_US |
dc.subject | Infection | en_US |
dc.subject | Drug Target | en_US |
dc.title | FKBPs in bacterial infections | en_US |
dc.type | Review | en_US |
dc.relation.journal | Biochimica Et Biophysica Acta-General Subjects | en_US |
dc.identifier.volume | 1850 | en_US |
dc.identifier.issue | 10 | en_US |
dc.relation.publicationcategory | other | en_US |
dc.contributor.department | TAÜ, Fen Fakültesi, Moleküler Biyoteknoloji Bölümü | en_US |
dc.contributor.institutionauthor | Ünal, Can Murat | |
dc.identifier.doi | 10.1016/j.bbagen.2014.12.018 | |
dc.identifier.startpage | 2096 | en_US |
dc.identifier.endpage | 2102 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.wos | WOS:000361263700015 | en_US |